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An ever-increasing body of literature describes compelling evidence that a subset of
young children on the autism spectrum show abnormal cerebral growth trajectories. In
these cases, normal cerebral size at birth is followed by a period of abnormal growth
and starting in late childhood often by regression compared to unaffected controls.
Recent work has demonstrated an abnormal increase in the number of neurons of the
prefrontal cortex suggesting that cerebral size increase in autism is driven by excess
neuronal production. In addition, some affected children display patches of abnormal
laminar positioning of cortical projection neurons. As both cortical projection neuron
numbers and their correct layering within the developing cortex requires the undisturbed
proliferation of neural progenitors, it appears that neural progenitors lie in the center
of the autism pathology associated with early brain overgrowth. Consequently, autism
spectrum disorders associated with cerebral enlargement should be viewed as birth
defects of an early embryonic origin with profound implications for their early diagnosis,
preventive strategies, and therapeutic intervention.
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INTRODUCTION
Autism spectrum disorders (ASDs, exchangeably used with autism in this review) comprise a
complex of neurodevelopmental behavioral anomalies centered on three core deficits: language
impairment, social impairment, and limited interests often accompanied by repetitive actions.
Typically, ASDs are diagnosed in early childhood exclusively through behavioral evaluation and
there is a strong association with gender as boys are affected four times as often as girls (Geschwind,
2011). Approaches to treatment are focused on improving social skills as well as language and
communication, and there are no medications currently available to alleviate the core symptoms.
Recent decades have seen a continuous rise in prevalence of ASDs in several countries (Palmer et al.,
2010; Parner et al., 2011; Paula et al., 2011). This trend appears not to be uniform though, as a recent
study in Sweden reported no changes in autism prevalence over a 10 year period (Lundström et al.,
2015) and part of the rise has been attributed to the expansion of diagnostic criteria and increased
reporting. In the United States in particular, where this worrisome trend has been closelymonitored
(Kong S.W. et al., 2012; Blumberg et al., 2013), the CDC reports (Blumberg et al., 2013) the number
of diagnosed cases has increased sevenfold over the last 20 years. Currently, the prevalence in the
US is close to one in 50 (Blumberg et al., 2013).
Formidable advances in untangling the complex genetic etiology of ASDs have been recently
enabled by the assembly of large DNA collections of affected individuals and their families,
particularly the Simplex Collection (SSC; Fischbach and Lord, 2010), and progress in DNA
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sequencing technologies (O’Roak et al., 2011, 2012; Iossifov
et al., 2012, 2014; Neale et al., 2012; Sanders et al., 2012). These
studies have identified two intriguing aspects of autism genetics.
First, causative genes in ASDs are characterized by an enormous
diversity involving hundreds and possibly up to a thousand
genes. Second, the genetic contribution largely stems from rare
variants in protein-coding genes, none of which accounting
for more than 1% of the total number of cases. This complex
landscape of autism genetics apparently underlies also the great
heterogeneity of endophenotypes, one of the major challenges in
identifying and defining neuropathological abnormalities that are
shared across the autism spectrum (Happé et al., 2006). However,
as the understanding of genetic causes increases and data on the
spatiotemporal expression and interaction of causative autism
genes, and the proteins they encode, become available the
opportunity arises to subclassify autism cases and recognize the
respective underlying pathology. For instance, several known
autism factors, such as Nrxn, Nlgn, and Shank have a defined
role in synaptic cohesion and function (Toro et al., 2010).
Coexpresssion network analyses of the encoding genes, implicate
early postnatal stages associated with neuronal differentiation
and synaptic maturation as probable points of vulnerability to
the development of ASDs (Parikshak et al., 2013). In contrast,
developmental regulators found to be causative in autism, such
as CHD8, TBR1, and FMR1, apparently form distinct networks
that converge on prenatal coexpression modules of developing
cortical projection neurons (Parikshak et al., 2013; Willsey et al.,
2013).
A SUBSET OF ASD CASES DISPLAYS
ALTERATIONS IN OVERALL AND
REGIONAL BRAIN GROWTH
TRAJECTORIES
The search for genetic determinants in ASDs has been
accompanied by an equally intense search for neuropathological
changes in the autistic brain. However, the survey for consistent
neuroanatomical changes across the autism spectrum has
been hampered by the heterogeneity of cases, rooted in very
different causes, and often associated with diverse comorbidities.
Nonetheless, in particular magnetic resonance imaging (MRI)
studies and postmortem analysis of brains of affected children
have produced convincing evidence that cerebral overgrowth
in early childhood is a defining feature in a subset of autism
cases (Courchesne et al., 2001, 2003; Sparks et al., 2002; Hazlett
et al., 2005). The size of this subset varies among studies,
as small proband cohorts appear to introduce considerable
variability, but may comprise approximately 20% of all ASD
cases (Fombonne et al., 1999; Nordahl et al., 2011). In these
cases, normal or even slightly reduced cerebral size at birth is
followed by a period a rapid growth within the first year, followed
by a period of slowed growth after 2–3 years of age (Redcay
and Courchesne, 2005; Courchesne et al., 2007, 2011a). The
cerebral cortex is the primary source of overgrowth; however,
other forebrain structures exhibit enlargement as well, most
prominently the amygdala, an important center of emotional
learning and memory processing (Sparks et al., 2002; Schumann
et al., 2004). Intriguingly, several studies reported that cerebral
overgrowth is not uniform, but rather regional with frontal and
temporal cortices predominantly affected while other aspects
are not affected (Carper et al., 2002; Kates et al., 2004; Hazlett
et al., 2005; Bloss and Courchesne, 2007; Schumann et al.,
2010). Interestingly, the higher-order cognitive processes affected
in ASDs such as language, sociability, and emotion correlate
well with these areas of pronounced hyperplasia suggesting
that pathological regional cortical expansion and autism core
deficiencies are tightly linked (Baron-Cohen and Belmonte, 2005;
Amaral et al., 2008). Furthermore, brain overgrowth appears
to indicate particular severity of symptoms and is associated
with regression, the increased loss of social an/or communicative
abilities later in life (Nordahl et al., 2011).
The inheritance patterns of megalencephaly remain uncertain
and their association to ASDs are complicated by the presence
of megalencephalic children without ASD symptoms. A recent
study demonstrated partial inheritance of brain size in families
with members on the spectrum, suggesting that enlarged brain
size predisposes affected individuals and likely presents an
endophenotype of ASD (Froehlich et al., 2013). Another study
found that ASD cases withmacrocephaly weremore likely to have
1st degree relatives with benign/non-ASD-related macrocephaly
(Fidler et al., 2000). ASD cases with brain sizes over the 75th
percentile (enlarged, but not classically defined as macrocephaly,
which is >97th percentile) had greater impairments in adaptive
functioning and had higher rates of immune dysfunction, as well
as their 1st degree relatives (Sacco et al., 2007). In these cases,
macrocephaly was generally found to associate with generalized
somatic overgrowth, a finding replicated in a separate study in
boys only (Campbell et al., 2014).
Intriguingly, developmental brain enlargement appears to be
a point of convergence for environmental ASD risk factors as
well, particularly cases associated with maternal inflammatory
response, referred to as maternal immune activation (MIA).
Studies have shown a positive association between early brain
overgrowth and maternal inflammation in a subset of ASD cases,
suggesting a link between inflammatory states and prenatal brain
development in ASD (Sacco et al., 2007; Nordahl et al., 2013).
Research into MIA associated with autoantibodies directed
against fetal brain proteins has provided additional insight in
this context, as targeted fetal brain proteins include factors
critical for neural progenitor proliferation and differentiation
(Braunschweig et al., 2013). Moreover, intraventricular injections
of maternal autoantibodies into mouse embryos result in
enhanced neural progenitor proliferation during development,
as well as increased neuronal cell size and larger brains in adults
(Martínez-Cerdeno et al., 2014).
ALTERED NEUROGENESIS IN ASDs
While early brain overgrowth has been recognized as a key
feature in a subset of young children on the autism spectrum, the
causes of this enlargement have not been exhaustively explained
even though an excess in excitatory projection neurons appears
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reasonable. Projection neurons comprise the vast majority of
neurons in the cortex (80%) and could with their dendrites,
synapses, axons, and myelin, produce the increase in gray and,
occasionally, white matter volumes reported in young autistic
children. Indeed, this assumption has been recently considerable
strengthened through work assessing and comparing neuron
numbers in autistic and normal children postmortem, which
found 67% more neurons in the prefrontal cortex of autism cases
(Courchesne et al., 2011b). Drastically altered neuron numbers
in postnatal life can be indicative of changes in developmental
neurogenesis, which in humans occurs largely during late
embryonic and early fetal development, from gestational weeks
7–20. As cell generation dominates cell elimination by at least a
factor of 100 in the developing brain (Rakic and Zecevic, 2000),
the contribution of cell death to megalencephaly during this
period appears negligible.
Proper developmental neurogenesis depends upon the tightly
regulated balance between symmetric divisions of radial glial
cells, that produce additional radial glial cells, and asymmetric
divisions, that generate intermediate progenitors and postmitotic
cells. Newly formed projection neurons, predominantly
generated by the symmetric divisions of intermediate progenitors
in the subventricular zone, migrate radially outward to establish
the six-layered neocortex by successively forming first the inner
and then the outer laminae (Gupta et al., 2002; Nadarajah and
Parnavelas, 2002; Kriegstein and Noctor, 2004). As symmetric
mitoses drive lateral expansion and asymmetric mitoses produce
radial growth of the cortical sheet, natural or pathological shifts in
the mode of neural progenitor division have the capacity to direct
cortical morphological outcomes and brain growth in general
(Fish et al., 2008). Consequently, changes in developmental
neurogenesis could, in addition to altered numeric output,
generate structural changes reflecting disturbances in neuron
generation. Indeed, such evidence has been produced by several
studies. A first inquiry in this area identified in four out of six
ASD cases focal cortical anomalies of misaligned projection
neurons and marginal zone heterotopia (Bailey et al., 1998). A
2007 study using both MRI and postmortem histological analysis
identified cortical lamination abnormalities and supernumerary
neuronal foci in seven out of eight examined ASD cases
(Hutsler et al., 2007). Wegiel et al. report in 12 out of 13 of
the autistic brains examined, findings of multifocal cerebral
dysplasia reflective of broad dysregulations of neurogenesis,
neuronal migration and maturation in addition to subcortical,
periventricular, hippocampal, and cerebellar heterotopias
(Wegiel et al., 2010). The analysis of seven additional affected
individuals revealed foci of cortical thinning, classified as
focal cortical dysplasia, affecting particularly the frontal lobes
(Casanova et al., 2013). These findings were further corroborated
by a more recent study that used molecular markers to identify
widespread patches of disorganized cortical layering in 10
out of 11 examined cases (Stoner et al., 2014). Focal cortical
dysplasia, a well-recognized cause of intractable epilepsy, provide
a possible explanation for the high prevalence of epilepsy as a
comorbidity in autism, with co-diagnoses reaching up to 40%
of autism cases (Danielsson et al., 2005; Mouridsen et al., 2011).
Collectively, these studies provide strong support for the concept
of altered neural progenitor proliferations as a key event in
pathological outcomes characteristic of a subtype of autism cases,
associated with developmental megalencephaly and focal cortical
lamination defects. The cellular substrate of megalencephaly is
likely provided by cortical projection neurons, but apparently
not by a concomitant increase in glia cells (Courchesne et al.,
2011b; Morgan et al., 2014) even though astrocytes are generated
by the same progenitor pool that generates projection neurons.
Similarly, cerebral white matter, largely composed of myelinated
axons of cortical projection neurons and glia, has not been found
to be significantly increased in young children on the spectrum
with megalencephaly (Hazlett et al., 2005; Friedman et al., 2006).
NEURAL PROGENITORS AND ASDs
In recent years, insight into the developmental neurogenic
basis of brain enlargement in autism has been substantially
aided by the discovery of genes causative in autism and
encoding regulators of neural progenitor proliferation (Figure 1).
Phosphatase and tensin homolog (PTEN) gene was the first
gene unambiguously linked to macrocephaly in autism (Goffin
et al., 2001; Butler et al., 2005; Buxbaum et al., 2007; Varga
et al., 2009). The gene was initially identified as a tumor
suppressor, frequently mutated in a variety of cancers and
apparently regulating cellular proliferation and cell cycle arrest
through the phosphatidylinositol 3-kinase (PI3K)/Protein kinase
B (PKB/Akt) pathway (Zhao et al., 2004). Nestin-cre mediated
conditional inactivation of Pten in mice closely replicated the
megalencephaly observed in humans, a phenotype largely driven
FIGURE 1 | Diagram summarizing findings on causative ASD
molecules that act on neural progenitor proliferation. Listings include
recognized molecular functions potentially underlying control over cellular
division. RGC, radial glial cell.
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by an increase in neural progenitor proliferation even though a
reduction in apoptosis was observed as well (Groszer et al., 2001).
Naturally, the detailed study of altered neural progenitor
proliferation and developmental neurogenesis in humans is
made impossible by ethical and practical considerations. All
insight depends on retrospective examination, ideally of young
brains, through MRI and the few tragic cases that become
accessible through tissue donation and postmortem analysis.
However, animal models that replicate aspects of human
phenotypic alterations and are experimentally accessible through
a wide variety of tools can provide recourse to a deeper
understanding of pathological neurogenesis in autism. Genetic
zebrafish and mouse models have dominated recent advances
in this area. For instance, a 2012 study in zebrafish to
ascertain the neurodevelopmental effects of the 29 genes
involved in 16p11.2 copy number variants provided interesting
results with respect to autism-relevant changes in brain
size (Golzio et al., 2012). 16p11.2 copy number variation
is causative in neurocognitive disorders with curiously both
duplications and deletions resulting in ASDs (Weiss et al.,
2008; McCarthy et al., 2009). The neuropathological outcomes
are opposite though, with deletions leading to macrocephaly
and duplications to microcephaly in humans. These phenotypic
outcomes were closely replicated in the respective zebrafish
experiments with either effect solely attributed to potassium
channel tetramerization domain containing-13 (KCTD13) while
shRNA-mediated knockdown of Kctd13 in mouse embryos
increases neural progenitor proliferation. The same study also
reported on an ASD proband with a 9 kbp deletion spanning
KCTD13 exons 3–5 further confirming the critical involvement
of this gene in autism. KCTD13 is a nuclear protein directly
interacting with DNA polymerase delta subunit 2 (POLD2)
and proliferating cell nuclear antigen (PCNA) and consequently
involved in DNA synthesis and replication (He et al., 2001).
While the mechanism by which KCTD13 influences progenitor
proliferation remains uncertain its interactions with POLD2
and PCNA suggest control over cell cycle progression. This
assumption is further strengthened by the functional interaction
of KCTD13 with the scaffold protein cullin 3 (CUL3) (Lin
et al., 2015). CUL3 is a component of E3 ubiquitin-protein
ligase complexes that among other roles ubiquitinate and degrade
cyclin E, thus directly controlling cell cycle progression (Singer
et al., 1999). Intriguingly, also for CUL3 two nonsense de novo
alleles in ASD cases were identified (Kong A. et al., 2012; O’Roak
et al., 2012) that specifically disrupt CUL3 interaction with
KCTD13 (Lin et al., 2015).
CHD8, which encodes a chromatin regulating DNA helicase,
has emerged as a key gene in ASDs with 9 de novo likely
gene-disrupting mutations identified in the SSC (O’Roak et al.,
2012; Iossifov et al., 2014). A broader search for disruptive
alleles that included in addition to ASDs also children exhibiting
developmental delay identified 12 additional CHD8 truncating
mutations (nonsense, frameshift, and canonical splice site)
(Bernier et al., 2014). Intriguingly, 80% of affected individuals
carrying likely causative CHD8 alleles exhibit macrocephaly,
a significantly higher percentage than overall macrocephaly
presentation in ASD cases of the SSC without CHD8 mutations,
possibly defining a subtype. For two of the affected children, head
circumference growth trajectories were available and confirmed
in the first 2months unusual growth of the orbital frontal head. In
these cases, increased head circumference persisted throughout
early childhood at or above the 97th percentile. Modeling of
the CHD8 phenotype in zebrafish embryos by gene knockdown,
produced megalencephalic morphants exhibiting an increase in
the otx2+ forebrain/midbrain neural progenitor population and
pointing at overproliferation of neural progenitors as the main
driver of the observed brain size increase (Bernier et al., 2014;
Sugathan et al., 2014).
WDFY3, similarly identified through surveys of causative de
novo variants in ASD from the SSC (two cases; Iossifov et al.,
2012, 2014), is an additional gene implicated in megalencephaly
and altered neural progenitor proliferation. Previous work has
characterized WDFY3 as a scaffold protein, required for the
selective autophagic degradation of macromolecular components
such as aggregation-prone proteins in a process described as
selective macroautophagy (Filimonenko et al., 2010). Loss of
Wdfy3 in mice has profound effects on neural progenitor
proliferation and neuronalmigration (Orosco et al., 2014).Wdfy3
mutant mice exhibit larger brains as a consequence of a relative
change in the mode of radial glia mitoses from asymmetric to
symmetric. This shift in the proliferative mode of radial glial
cells increases the progenitor population and, as a consequence,
cerebral size. Furthermore, since progenitor expansion and
cortical neurogenesis proceeds in a spatiotemporal gradient
during development, initiated anterolaterally and concluded
posteromedially (Caviness et al., 2009), the proliferative changes
in Wdfy3 mutant mice disproportionally affect the anterolateral
areas of prolonged neurogenic period. This important aspect
replicates similar findings reported in some MRI studies of
brains of affected children, in which frontal and temporal
cortices were predominantly affected by size increase (Carper
et al., 2002; Kates et al., 2004; Hazlett et al., 2005; Bloss and
Courchesne, 2007; Schumann et al., 2010). Importantly, this
regionality in cerebral overgrowth may be intimately linked to
the core behavioral pathology in affected children. In humans
these areas contain the orbitofrontal and ventrolateral prefrontal
cortex, the superior temporal sulcus, and the insula of the
temporal cortex, key regions in determining social value, reward,
reinforcement, interoception, and emotional processing that are
centrally affected in ASDs (Pelphrey and Carter, 2008; Redcay,
2008; McPartland et al., 2011; Gotts et al., 2012; Gasquoine,
2014).
The mechanism by which Wdfy3 exerts control over cellular
division remains uncertain, but expression analysis revealed
its specific upregulation in neural progenitors during mitosis
(Orosco et al., 2014), possibly acting in the autophagic
degradation of specific proteins instrumental in cell cycle control,
as the cell cycle inWdfy3mutant mice is shortened. Interestingly,
WDFY3, the autophagy receptor SQSTM1/p62, and the ubiquitin
E3 ligase TRAF6 form a complex that ensures the ubiquitination
and efficient clearance of midbody ring derivatives after mitosis
(Isakson et al., 2013). Apparently, retention of the midbody
ring in daughter cells is associated with the maintenance of
undifferentiated characteristics in stem and cancer cells (Ettinger
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et al., 2011; Kuo et al., 2011), providing a possible explanation for
the increase in the progenitor population ofWdfy3mutants.
CONCLUSION AND FUTURE STEPS
Evidence accumulated over the last few years strongly supports
the notion that a subgroup of children on the autism spectrum
may exhibit unusual brain enlargement soon after birth. This
megalencephaly affects predominantly the cerebrum and is
associated with an increase in the number of neurons in affected
areas. The most plausible explanation for this unusual cerebral
overgrowth appears to be an increase in the proliferation of
neural progenitors during embryonic development, which has
been convincingly corroborated by animal models. Intriguingly,
developmental megalencephaly may be a point of confluence
for both genetic and environmental factors in ASDs as work
on maternal inflammation during pregnancy suggests. Thus,
early brain overgrowth in autism has to be viewed as a
birth defect rooted in the altered proliferative program of
neural stem cells during the earliest stages of developmental
neurogenesis. Importantly, as environmental factors appear to
be involved in autism development as well, nutrients, drugs,
pollutants, toxins, pathogens, and other maternal exposures
should be carefully evaluated for their possible contributions
to altered neurogenesis in the embryo/fetus and associated
megalencephaly in autism. Harmful exposures, assessed and
recognized by in vitro assays or suitable animal models,
could be individually targeted through preventive strategies
with positive epidemiological effects. The prospect that neural
progenitors are centrally involved in pathological changes that
define a subset of autism cases opens up the possibility for the
development of novel biomarker-based diagnostics exploiting
proliferative changes of stem cell compartments. Diagnostic
markers, validated in peripheral samples, such as blood, could
be applied early in life and possibly supplement the current
regime of behavioral evaluation for added diagnostic certainty.
At risk children, recognized through biomarkers, could be
submitted earlier to behavioral intervention before treatment-
resistant brain defects develop. In addition, ASDs rooted in
altered developmental neurogenesis may define a specific subtype
within the spectrum with special considerations with respect
to comorbidities and trajectories, requiring distinct pathways to
intervention.
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